Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
97.104,31
-0,11%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY) Notizie

Alnylam Pharmaceuticals Inc

ALNY
245,44
6,57 (2,75%)
21 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/12/202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202422:05EDGAR2Form 144 - Report of proposed sale of securities
27/11/202423:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202423:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202423:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202423:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202423:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202422:06EDGAR2Form 144 - Report of proposed sale of securities
27/11/202413:00BWAlnylam to Webcast Presentation at Piper Sandler 36th Annual..
25/11/202413:00BWAlnylam Announces U.S. Food and Drug Administration..
17/11/202415:30BWAlnylam Announces Interim Phase 1 Data of Nucresiran..
04/11/202414:00BWAlnylam to Webcast Presentations at Upcoming November..
31/10/202413:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/10/202413:10EDGAR2Form 8-K - Current report
31/10/202413:00BWAlnylam Pharmaceuticals Reports Third Quarter 2024 Financial..
30/10/202413:00BWAlnylam to Showcase Latest Data from TTR Franchise and..
18/10/202414:15PRNCAAlnylam Canada signe une lettre d'intention de l'Alliance..
17/10/202415:12BWAlnylam reicht bei der Europäischen Arzneimittelagentur..
17/10/202414:00BWAlnylam to Webcast Conference Call Discussing Third Quarter..
16/10/202414:00BWAlnylam Submits Regulatory Application to the European..
10/10/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/10/202413:00BWAlnylam Submits Supplemental New Drug Application (sNDA) to..
03/10/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202422:08EDGAR2Form 3 - Initial statement of beneficial ownership of..
29/9/202415:00BWAlnylam Highlights New Data From HELIOS-B Study of..
26/9/202414:00BWAlnylam to Webcast TTR Investor Day
30/8/202422:03BWAlnylam présente les résultats détaillés de l'étude de phase..
30/8/202419:10BWAlnylam präsentiert detaillierte Ergebnisse der positiven..
30/8/202412:00BWAlnylam Presents Detailed Results from the Positive HELIOS-B..
28/8/202422:00BWAlnylam to Webcast Presentations at Upcoming September..
23/8/202402:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/8/202423:10EDGAR2Form 144 - Report of proposed sale of securities
14/8/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/8/202422:07EDGAR2Form 144 - Report of proposed sale of securities
08/8/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202404:08BWEuropäischer Kardiologenkongress 2024: Alnylam legt..
08/8/202401:04BWAlnylam présentera des résultats détaillés de l'étude..
07/8/202414:00BWAlnylam to Present Detailed Results from the HELIOS-B Phase..
06/8/202422:07EDGAR2Form 144 - Report of proposed sale of securities
03/8/202402:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202422:01EDGAR2Form 144 - Report of proposed sale of securities
01/8/202414:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202414:11EDGAR2Form 8-K - Current report
01/8/202414:00BWAlnylam Pharmaceuticals Reports Second Quarter 2024..
18/7/202414:00BWAlnylam to Webcast Conference Call Discussing Second Quarter..
13/7/202402:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/7/202422:40EDGAR2Form 144 - Report of proposed sale of securities
24/6/202413:00BWAlnylam Reports Positive Topline Results from HELIOS-B Phase..
01/6/202401:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202422:01EDGAR2Form 144 - Report of proposed sale of securities
Apertura: 238,81 Min: 235,93 Max: 247,21
Chiusura: 238,87

La tua Cronologia

NASDAQ
ALNY
Alnylam Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network